Originally published in World Intellectual Property Review 3 2021 After surviving the Great Patent Cliff of 2011–2016,...
Strategies for generic/biosimilar market entry in Australia
read more
Home / News / Pearce IP Blog
ALL BLOGS BY
Alex May
Alex is an intellectual property disputes lawyer with twelve years’ experience and a track record of obtaining successful outcomes for clients. He specialises in advising pharmaceutical companies on patent litigation and related matters and has a technical background in genetics.
Alex has represented some of the largest pharmaceutical companies in the world in patent disputes relating to blockbuster antiviral, autoimmunity and chemotherapy medicines.
See Alex's full profile
Wrinkle for supplier of Botox ‘alternative’ as Court finds trade mark infringed, Australian Consumer Law breached
The Full Federal Court has held a supplier of cosmetic products (Self Care) liable to Allergan for infringing its...
New .au domain names coming to Australia
New .au domain names will be available in Australia from 24 March 2022. From this date, individuals, businesses and...
Federal Court Confirms Higher Bar for Sufficiency and Support in Australian Patent Law
Nalco Patent Application Claiming Inhibitors of Silica Deposits Invalid: a Question of Scale
A recent decision of Justice Burley in the Federal Court of Australia confirms that the bar for sufficiency and...
PTEs in Australia – more hard lessons for patentees from the Federal Court
The Australian Federal Court has confirmed in Merck Sharp & Dohme Corp. v Sandoz Pty Ltd [2021] FCA 947 that, when...
Let the applicant beware!
Misrepresentations are not just limited to examples
Although Australia has taken steps in recent years to harmonise its patent laws with those around the globe,...
How medicine repurposing could unravel the pharma industry in Australia
TGA seeks consultation on issues relating to the registration of off-label medicines: Part 2
As discussed in Part 1 of this blog series, TGA has invited submissions by 23 March 2021 on its consultation paper...
Exclusive licensees: are you stuck in a “No Standing” zone?
Under Australian law, patent infringement proceedings may be started in the Australian Federal Court only by a...
Supply of essential oil for topical use infringes method of treatment patent claims
Supply of essential oil for topical use infringes method of treatment patent claims Justice Nicholas’ 96-page judgment...
Preliminary discovery not justified by fear of a future product launch
In Pfizer Ireland Pharmaceuticals v Sandoz Pty Ltd [2020] FCA 1648, the Federal Court of Australia declined to order...